MarketCap
Facebook
X
TelegramAnnual report 2024
added 01-03-2026
BioLineRx Ltd. Total Non Current Liabilities 2011-2026 | BLRX
Annual Total Non Current Liabilities BioLineRx Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 8.22 M | 8.16 M | 1.36 M | 251 K | 552 K | 1.5 M | 5.27 M | 2.91 M | 50.7 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.22 M | 50.7 K | 3.14 M |
Quarterly Total Non Current Liabilities BioLineRx Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 3.58 M | - | 7.52 M | - | 14.6 M | - | 12 M | - | 8.22 M | - | 11.6 M | - | 8.16 M | - | 689 K | - | 1.36 M | - | - | - | 251 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.6 M | 251 K | 6.81 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.37 | -8.67 % | $ 350 M |  Britain |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
Adagene
ADAG
|
158 M | $ 1.65 | 6.11 % | $ 92.9 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
73.6 K | $ 3.43 | -2.69 % | $ 8.25 B |  Australia |
 |
Biogen
BIIB
|
9.03 B | $ 177.93 | -4.15 % | $ 25.9 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
686 M | $ 65.89 | -0.06 % | $ 8.81 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M |  France |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
AVROBIO
AVRO
|
276 K | - | 1083.1 % | $ 745 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | Britain |
 |
AstraZeneca PLC
AZN
|
30.8 B | $ 94.4 | 0.82 % | $ 96.9 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
374 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
48 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
22.3 M | - | -7.31 % | $ 87 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
101 M | $ 214.55 | 2.77 % | $ 5 B |  Danmark |
 |
Codiak BioSciences
CDAK
|
119 M | - | -55.98 % | $ 2.15 M | USA |
 |
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
59.9 B | $ 55.84 | 0.13 % | $ 113 B | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
4.4 M | - | - | $ 7.29 B | USA |
 |
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M |  Canada |
 |
Caladrius Biosciences
CLBS
|
254 K | - | -16.75 % | $ 25.8 M | USA |
 |
Clearside Biomedical
CLSD
|
4.72 M | - | - | $ 25.3 M | USA |
 |
Chimerix
CMRX
|
196 K | - | - | $ 756 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
23.6 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
341 M | $ 106.88 | 4.6 % | $ 27.2 B | Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.63 M | $ 4.18 | -1.65 % | $ 9.1 B |  Israel |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Catalyst Biosciences
CBIO
|
981 K | $ 11.09 | 1.0 % | $ 730 M | USA |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M | Israel |
 |
Coherus BioSciences
CHRS
|
189 M | $ 1.69 | 2.12 % | $ 159 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 28.99 | -1.39 % | $ 1.4 B | USA |
 |
Celldex Therapeutics
CLDX
|
17.3 M | $ 25.71 | 0.16 % | $ 1.66 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
1.17 M | - | - | $ 1.2 B | USA |
 |
Cellectis S.A.
CLLS
|
109 M | $ 4.24 | -0.47 % | $ 116 M | France |
 |
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | USA |
|
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | USA |
 |
Brickell Biotech
BBI
|
146 K | - | -5.38 % | $ 6.06 M | USA |